Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
12/2008
12/24/2008CN100444860C Compound Chinese medicinal extract mixture and its prepration method
12/24/2008CN100444854C Ointment for treating phlebitis and method for preparing same
12/24/2008CN100444851C Use of chrysanthemum total flavone for preparing drugs for treating arythmia
12/24/2008CN100444847C Micronize diosmin and hesperidine composition suppository
12/24/2008CN100444845C Biologic adhesion preparation of total saponin of notoginseng for gastrointestinal tract
12/24/2008CN100444843C Sustained release oral preparations of fasudil hydrochloride
12/24/2008CN100444839C Treatment of chemokine mediated diseases
12/24/2008CN100444836C Injecting composition containing Sodium Danshensu
12/24/2008CA2727391A1 Azapeptides as cd36 binding compounds
12/24/2008CA2692249A1 Pyrazolone derivative and pde inhibitor containing the same as active ingredient
12/24/2008CA2692248A1 Pyridazinone derivative and pde inhibitor containing the same as active ingredient
12/24/2008CA2691991A1 Treatment of pulmonary hypertension with carbonic anhydrase inhibitors
12/24/2008CA2690762A1 .alpha.-chloro and .alpha.-bromo phosphonate analogs of lysophosphatidic acid and methods of making and using thereof
12/24/2008CA2690603A1 Targeted oxygen delivery via intravenous or intra-arterial infusion of oxygenated polymerized hemoglobin solutions
12/24/2008CA2690545A1 Substituted bicyclic heteroaryl compounds and their use
12/24/2008CA2690527A1 Substituted furopyrimidines and use thereof
12/24/2008CA2690379A1 Substituted piperazines
12/24/2008CA2689525A1 Cetp inhibitors derived from benzoxazole arylamides
12/24/2008CA2689523A1 Cetp inhibitors derived from benzoxazole arylamides
12/23/2008US7468444 Crystalline polymorphic dosage forms of anticholesterol agents; statins; suspending atorvastatin hemi-calcium in water for 16 hours convert the atorvastatin hemi-calcium into Form I
12/23/2008US7468435 Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same
12/23/2008US7468385 Preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension; 3-(5-((3-chlorobenzyl)sulfanyl)-4-(3-methoxypropyl)-4H-1,2,4-triazol-3-yl)-N-(2-methoxybenzyl)propanamide
12/23/2008US7468380 Nitrogen-containing aromatic derivatives
12/23/2008US7468368 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
12/23/2008US7468367 depression; anxiety; addictions; obsessive compulsive disorder; affective neurosis/disorder; depressive neurosis/disorder, anxiety neurosis; dysthymic disorder; behaviour disorder; mood disorder; sexual dysfunction; psychosexual dysfunction; sex disorder, sexual disorder; schizophrenia; manic depression;
12/23/2008US7468361 For therapy of skin conditions selected from the group consisting of dermatitis, eczema, keratosis, lack of skin firmness, wrinkles, lack of dermal hydration and insufficient sebum secretion
12/23/2008US7468359 Compositions comprising oxophosphonate-based metalloproteinase inhibitors
12/23/2008US7468276 Bloodless mammalian placenta for use in generating multipotent stem cells
12/23/2008US7468270 Probiotic strains, a process for the selection of them, compositions thereof, and their use
12/23/2008US7468183 using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B; preparation of the antibody using a fragment library
12/23/2008CA2424664C Novel non-imidazole compounds
12/23/2008CA2331685C Use of compounds for the elevation of pyruvate dehydrogenase activity
12/23/2008CA2187990C Pharmaceutical compositions comprising l-carnitine, or derivative thereof, and trihydroxy or tetrahydroxystilbene
12/18/2008WO2008154347A1 Spirobenzoazepines as vasopressin antagonists
12/18/2008WO2008154023A1 Novel uses of ppar delta agonists
12/18/2008WO2008154008A1 Methods and compositions for inhibiting toll-like receptor mediated immune responses
12/18/2008WO2008153902A2 Urotensin ii receptor antagonists
12/18/2008WO2008153857A1 Dual-acting benzoimidazole antihypertensive agents
12/18/2008WO2008153705A2 Methods of treating, diagnosing and detecting fgf21-associated disorders
12/18/2008WO2008153220A1 Prophylactic or therapeutic agent for vascular disease
12/18/2008WO2008153182A1 Morpholine derivative
12/18/2008WO2008153135A1 Naphthalene derivative
12/18/2008WO2008153129A1 Agent for lowering uric acid level
12/18/2008WO2008153027A1 Pyrroloquinoline derivative and use thereof
12/18/2008WO2008152387A1 Quinazoline derivatives as pi3 kinase inhibitors
12/18/2008WO2008152226A2 Homogeneous and stable composition rich in oleaginous substances based on a milk product, method for the preparation thereof and uses thereof
12/18/2008WO2008151847A1 Autoantibody binding peptides and their use for the treatment of vascular diseases
12/18/2008WO2008151637A2 Neuroplastin derived peptides
12/18/2008WO2008151428A1 Novel compositions for modulating mrna translation
12/18/2008WO2008125279A9 Atrial-radiofrequency catheter ablation mediated targeting of mesenchymal stromal cells
12/18/2008WO2008124857A8 Plant extract, and use thereof
12/18/2008WO2008100457A3 Functionally selective alpha2c adrenoreceptor agonists
12/18/2008WO2008076862A3 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors
12/18/2008WO2008073392A3 Compositions and methods for cardiac tissue protection and regeneration
12/18/2008WO2007100795A3 Combinations comprising a histone deacetylase inhibiting agent and a nuclear hormone receptor ligand for treating cardiovascular conditions
12/18/2008US20080312462 Process for the manufacture of HMG-CoA reductase inhibitory mevalonic acid derivatives
12/18/2008US20080312410 Cysteine-containing peptide tag for site-specific conjugation of proteins
12/18/2008US20080312336 Preventive and/or Therapeutic Agent for Diabetic Vascular Disorder and Respiratory Disorder
12/18/2008US20080312333 Agent for Preventing/Ameliorating Life Style-Related Diseases Containing Turmeric Essential Oil Component
12/18/2008US20080312330 Methods for Reducing Mortality and Morbidity by Postoperative Administration of a Pharmacologic Cardiovascular Agent
12/18/2008US20080312311 Crystalline forms of 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine
12/18/2008US20080312310 Compounds, Compositions and Methods
12/18/2008US20080312273 Quinoline Derivatives Having Vegf Inhibiting Activity
12/18/2008US20080312267 Diagnosis and Treatment of Diseases Arising from Defects in the Tuberous Sclerosis Pathway
12/18/2008US20080312263 Pharmaceutical compositions for the prevention and treatment of atherosclerosis
12/18/2008US20080312261 4- (4-Bromo-2-Fluoroanilino) -6- Methoxy-7- (1-Methylpiperidin-4-Ylmethoxy) Quinazoline Monohydrate
12/18/2008US20080312259 SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE
12/18/2008US20080312257 Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists
12/18/2008US20080312247 Substituted piperazines
12/18/2008US20080312242 7-aryl-3, 9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases
12/18/2008US20080312241 Cicletanine and PKC inhibitors in the treatment of pulmonary and cardiac disorders
12/18/2008US20080312234 Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
12/18/2008US20080312233 Therapeutic Morpholino-Substituted Compounds
12/18/2008US20080312227 Substituted Pyrido(2,3-D) Pyrimidine Derivatives Useful as Medicines for the Treatment of Autoimmune Disorders
12/18/2008US20080312219 Biologically active methylene blue derivatives
12/18/2008US20080312210 Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
12/18/2008US20080312199 Treatments of therapy resistant diseases and drug combinations for treating the same
12/18/2008US20080312191 Novel Urokinase Inhibitors
12/18/2008US20080312189 Cadasil Treatment with Cholinesterase Inhibitors
12/18/2008US20080312153 prevention or treatment of disease associated with hyperglycemia: diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity; e.g. 4-[(4-{3-[1-carbamoyl-1-(methyl)-ethylcarbamoyl]propyl}-2-methylphenyl)methyl]-3-( beta -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole
12/18/2008US20080312146 METH1 and METH2 Polynucleotides and Polypeptides
12/18/2008US20080312139 In an injectable form and to be administered through infiltrations inside and around cutaneous chronic ischemic ulcerative wounds as to prevent diabetic limb amputation
12/18/2008US20080312129 Use of Mas G-Protein-Coupled Receptor Agonists and Antagonists, as Apoptotic-Activity Modulators for Study, Prevention and Treatment of Diseases
12/18/2008US20080312098 Use of a Gip Promoter Polymorphism
12/18/2008US20080311156 Vaccines
12/18/2008US20080311121 Antibody antagonists of ve-cadherin without adverse effects on vascular permeability
12/18/2008US20080311118 Vascular endothelial cell growth factor antagonists and uses thereof
12/18/2008US20080311113 Method for treating adamts-5-associated disease
12/18/2008US20080311105 Reversibly Inactivated Acidified Plasmin
12/18/2008US20080311099 Pyridoxal-5-Phosphate and Related Compounds in Combination With Therapeutic Cardiovascular Compounds for Treating Angina
12/18/2008US20080311051 Caspase-2 Inhibitors And Their Biological Applications
12/18/2008US20080311037 Compounds which bind PSMA and uses thereof
12/18/2008US20080311034 Anti-Tissue Factor Antibodies and Compositions with Enhanced Effector Function
12/18/2008DE60132178T2 CRISTALLINSALZE VON 7-i4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-iMETHYL(METHYLSULFONYL)AMINO PYRIMIDIN-5-YL -(3R,5S)-3,5-DIHYDROXYHEPT-6-ENSÄURE CRISTALLI SALTS OF 7-I4 (4-fluorophenyl) -6-isopropyl-2-iMETHYL (methylsulfonyl) PYRIMIDIN AMINO-5-YL - (3R, 5S) -3,5-dihydroxyhept-6-enoic acid
12/18/2008DE102007027800A1 Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung Substituted bicyclic heteroaryl compounds and their use
12/18/2008DE102007027799A1 Substituierte Furopyrimidine und ihre Verwendung Substituted Furopyrimidine and their use
12/18/2008CA2690600A1 A drug delivery system for the prevention of cerebral vasospasm
12/18/2008CA2690348A1 Morpholine derivative
12/18/2008CA2690080A1 Urotensin ii receptor antagonists
12/18/2008CA2687746A1 Methods of treating, diagnosing and detecting fgf21-associated disorders
1 ... 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 ... 1595